due lack growth visibl
cant control cant control pressur remain
walgreen recent result highlight number challeng current face
busi primarili driven on-going reimburs pressur well lower-than-
expect script growth quarter convers investor remain focus
headwind posit lever busi importantli opex
ration open-end question partnership model pay
head next quarter potenti upsid option increas flu-rel
script off-set time reimburs true-up weigh
cadenc profit cours year total continu downward
pressur reimburs appear see clear end without operationally-
driven improv better growth vs continu contribut opex cut
think stock continu lag compar compani perform therefor
reiter under-perform rate price object
adjust estim fulli reflect true-up time
follow detail second review quarter adjust estim
accur captur expect cadenc cours year back
review slightli lower ep also
lower ep growth driven anoth
step-up opex reduct share repurchas contribut calendar
flip await color also drug retail
includ mass merchandis grocer pace reimburs pressur
magnitud felt across market appear differ compani compani
also look increment updat variou partnership
expect start contribut increment ebit growth
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
walgreen follow complet rite
aid store acquisit largest global
pharmaci nearli store us
alon compani also oper intern
pharmaci busi primarili compos
boot pharmaci unit kingdom
allianc healthcar intern wholesal
distributor pharmaceut medic
product europ walgreen headquart
under-perform rate predic
pressur competit dynam
potenti increment competit
amazon small step market core
profit dollar growth slow think limit
visibl creat challeng near-term
stock perform view range-bound
exhibit walgreen earn estim actual includ annual ep guidanc chang
exhibit forward p/e complet decoupl valuat
exhibit discount price-to-earnings multipl
exhibit rx suppli chain valuat rel tight band last two year
exhibit short interest recent converg rx suppli chain compani although short interest post-deal close
price object base ep multipl
five-year averag absolut basi around discount five-year
averag reflect view walgreen core retail pharmaci busi long-
term structur pressur must diversifi stabl busi line improv
upsid risk better expect gener save new partnership
healthcar area labcorp etc support long-
term growth addit volum econdisc/rit aid contribut
addit new partnership faster expect growth prime therapeut
relationship downsid risk po on-going price reimburs pressur
higher prescript attrit part relationship integr risk
risk amazon anoth disrupt forc enter suppli chain market lack
available/app attract capit deploy opportun
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
